Helixmith Appoints Dr. Park Young-joo as New Head of U.S. Corporation

[Asia Economy Reporter Hyungsoo Park] Helixmith announced on the 9th that Dr. Park Young-joo, head of clinical development, has been appointed as the head (CEO) of Helixmith's U.S. subsidiary.

CEO Park Young-joo earned a master's and doctoral degree in statistical epidemiology from Seoul National University Graduate School of Public Health. He built expertise in clinical trials while working in the pharmaceutical and biotech industries. From 1996, he gained 20 years of experience in various areas of clinical development, including clinical trial planning, data management, biostatistics, safety management, MW (Medical Writing), and global clinical management at global pharmaceutical companies MSD and Sanofi.

CEO Park joined Helixmith in 2020 and has led the clinical division, especially U.S. clinical trials, alongside CEO Kim Sun-young.

Helixmith CEO Kim Sun-young introduced him by saying, "CEO Park Young-joo has high expertise in clinical trials and understands the operational details well. He is a professional with cost-efficient thinking and a strong sense of responsibility for his work."

Since last November, CEO Kim has been focusing on business development tasks such as licensing of Enzencis (VM202), preparation for marketing approval, and market entry. Among various clinical development tasks, she will continue to work as a team leader in medical science and development strategy.

This content was produced with the assistance of AI translation services.